Список проголосовавших за комментарий " On The Wires<ul><li>Cemtrex (<strong>CETX</strong>) reminded rights holders and broker-dealers of the January 20 subscription expiration date intended to help them successfully participate in the process and fairly subscribe to purchase units in the offering. The offering of units, which can be purchased for $10.00 each, consist of one share of series 1 preferred stock, paying cumulative dividends at the rate of 10% of the purchase price per year, and two series 1 warrants, each to purchase one share of Cemtrex's common stock at $6.31 per share for a period of five years after the closing of the offering. On January 17, 2017, the closing price of Cemtrex's common stock, as reported by the Nasdaq Capital Market, was $6.80 per share.</li><li>ARCA biopharma (<strong>ABIO</strong>) announced that the 150th patient has been randomized into GENETIC-AF, a seamless Phase 2B/3 clinical trial evaluating Gencaro(bucindolol hydrochloride) as a potential treatment for atrial fibrillation. The Company expects the outcome of this interim analysis in the third quarter of 2017.</li><li>Global Blood Therapeutics (<strong>GBT</strong>) announced enrollment of the first patient in the HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study, a pivotal Phase 3 clinical trial of GBT440 in people with sickle cell disease (SCD). The HOPE Study will be conducted at leading SCD sites globally and is expected to enroll up to 400 adults and adolescents with SCD who have had at least one episode of vaso-occlusive crisis (VOC) in the previous year.</li><li>UQM Technologies Inc. (<strong>UQM</strong>) announced the receipt of a new follow-on order from Proterra for PowerPhase HD electric drive systems, to be manufactured and shipped throughout 2017. Proterra will continue to increase its production capacity in 2017 as an increasing number of transit agencies see zero-emission buses as a credible and proven alternative to diesel, CNG, and hybrid buses. Proterra has fleets active in numerous cities throughout the US. Proterra's expansion is continuing to manifest as new investments and investors are attracted to their leading edge bus technology utilizing the UQM electric powertrain system.</li><li>Fusion (<strong>FSNN</strong>) announced that it has signed a three year, $100,000 contract with a resource optimization and business process software company in the metropolitan Washington, D.C. area.</li><li>FactSet (<strong>FDS</strong>) announced that it has strengthened its relationship with Axioma, a leading provider of enterprise risk management, portfolio construction and risk and regulatory reporting solutions. The strategic relationship includes making Axioma's linear fixed income and multi-asset class model available on FactSet and expands the multi-asset class risk models already available through FactSet.</li></ul>"